China-based Pacific Shuanglin Bio-pharmacy Co., Ltd (SHE: 000403) has formed a strategic partnership with Shenzhen-based XtalPi Holdings Limited (HKG: 2228). The collaboration aims to enhance technological innovation and drive high-quality development in the blood products industry through joint efforts in new product development, research, and intelligent management of production quality.
Collaboration Details
The partnership will focus on several key areas:
- Drug R&D and Optimization: Accelerating the development of blood products and other drugs, shortening product launch cycles, and reducing R&D costs.
- Intelligent Production and Quality Management: Implementing intelligent management solutions for the entire lifecycle of blood product production and quality management.
- Protein Structure and Function Research: Conducting simulation analyses of existing plasma protein products and exploring protein structures and functions in plasma to support product upgrades and market applications.-Fineline Info & Tech
